News and information about universal access to health care; the impact of restrictive policies and financial challenges on access to treatment; drug stock-outs; and scaling up services.

Access to medicines and treatment: latest news

Access to medicines and treatment resources

Access to medicines and treatment features

Access to medicines and treatment news from aidsmap

More news

Access to medicines and treatment news selected from other sources

  • Global ingredient shortage caused ARV stockouts

    A worldwide shortage of an active pharmaceutical ingredient is the reason behind the anti-retroviral (ARV) medication shortfall across the country, the department of health confirmed. The anti-retroviral drug called Lamivudine is currently in short supply globally and this has affected ARVs that contain this ingredient.

    07 June 2019 | Health-e
  • This drug could end HIV. Why hasn't it? (Podcast)

    Dr. Robert Grant developed a treatment — a daily pill known as pre-exposure prophylaxis, or PrEP — that could stop the AIDS crisis. We look at why that hasn’t happened.

    06 June 2019 | New York Times
  • WHO agrees watered-down resolution on transparency in drug costs

    Countries at the World Health Organization agreed on Tuesday to push for clearer drug pricing, after watering down a draft resolution that would have also required pharmaceutical firms to disclose the cost of making medicines.

    02 June 2019 | Reuters
  • World Health Assembly Approves Milestone Resolution On Price Transparency

    The World Health Assembly today approved a milestone resolution to support greater public disclosure of prices for medicines and other health products – capping a nail-biting series of negotiations that continued until the very moment the measure came to the floor. In a highly unusual move, Germany, the United Kingdom and Hungary “disassociated” themselves from the measure, “Improving the transparency of markets for medicines, vaccines and other health products,” complaining that its far-reaching implications were not fully appreciated, and that the four-month review period since the draft resolution’s submission by lead sponsor Italy had been insufficient.

    02 June 2019 | Health Policy Watch
  • UK's biggest sexual health clinic has just dropped its PrEP prices

    PrEP has become more affordable at London’s leading sexual health clinic. The 56 Dean Street clinic opened its PrEP Shop in February last year and provides the HIV preventative medication for those eligible for NHS care. It will cost as little as £17.50 per month.

    02 June 2019 | Gay Star News
  • Medicare decides against tighter management of HIV drugs

    The Department of Health and Human Services will continue barring Medicare Part D plans from applying the drug utilization management tools prior authorization and step therapy for beneficiaries taking HIV antiretroviral drugs. A rule proposed in November 2018 would have permitted such practices. Gilead voiced opposition to the original proposal, saying physicians need to have the flexibility to prescribe the right medicines for patients.

    21 May 2019 | BioPharma Dive
  • Mexican official resigns as HIV drug shortage sparks outcry

    A top Mexican health official said on Thursday that he had resigned amid growing anger over drug shortages that have left hundreds of HIV patients without life-saving medicines.

    10 May 2019 | Reuters
  • Gilead Will Donate Truvada to U.S. for H.I.V. Prevention

    Officials at the Department of Health and Human Services said the donation came about “as a result of discussions between the Trump administration and Gilead.” Critics said it would not be enough to end the AIDS epidemic and questioned the company’s motives.

    10 May 2019 | The New York Times
  • Generic HIV prevention drug coming in 2020, Gilead says

    "Gilead reached an agreement with Teva Pharmaceuticals in 2014 to allow the early launch of a generic version of Truvada into the market in 2020, a year earlier than required," wrote Douglas Brooks, Gilead's executive director for community engagement, in an email shared with NBC News by the advocacy group PrEP4All.

    09 May 2019 | CNBC
  • Official Statement responding to Gilead Sciences’ announcement that it will allow Teva to Manufacture a Generic Version of Truvada

    While Gilead’s announcement that generic Truvada will be made available in the United States a year early is a victory for the LGBTQ+ community, for HIV activists, and for U.S. taxpayers, this should only be the beginning. Even their announcement today leaves Gilead with exclusive rights to Truvada as PrEP for another 15 months and Teva as the only generic manufacturer on the U.S. market. This will do little to reduce the price in a way that will increase access and PrEP4All remains suspicious of the terms and lack of transparency surrounding the Teva settlement.

    09 May 2019 | Breakthepatent.org
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.